Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recent observations on the clinical pharmacology of (-)deprenyl.

Literature DB >> 745017

Recent observations on the clinical pharmacology of (-)deprenyl.

G M Stern, A J Lees, M Sandler.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1978 PMID： 745017 DOI： 10.1007/bf01246961

Source DB: PubMed Journal: J Neural Transm Impact factor: 3.575

× No keyword cloud information.

10 in total

1. Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors: T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188

2. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors: W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal: J Neural Transm Date: 1975 Impact factor: 3.575

3. The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle.

Authors: M Jouvet
Journal: Ergeb Physiol Date: 1972

Review 4. The clinical physiology of side effects in long-term L-DOPA therapy.

Authors: A Barbeau
Journal: Adv Neurol Date: 1974

5. Deprenyl is metabolized to methamphetamine and amphetamine in man.

Authors: G P Reynolds; J D Elsworth; K Blau; M Sandler; A J Lees; G M Stern
Journal: Br J Clin Pharmacol Date: 1978-12 Impact factor: 4.335

6. Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor.

Authors: M H Lader; G Sakalis; M Tansella
Journal: Psychopharmacologia Date: 1970-08-19

7. Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment.

Authors: P C Waldmeier; A E Felner
Journal: Biochem Pharmacol Date: 1978-03-01 Impact factor: 5.858

8. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Authors: J D Elsworth; V Glover; G P Reynolds; M Sandler; A J Lees; P Phuapradit; K M Shaw; G M Stern; P Kumar
Journal: Psychopharmacology (Berl) Date: 1978-04-14 Impact factor: 4.530

9. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors: W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal: Lancet Date: 1977-02-26 Impact factor: 79.321

10. Deprenyl in Parkinson's disease.

Authors: A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal: Lancet Date: 1977-10-15 Impact factor: 79.321

10 in total

9 in total

Recent observations on the clinical pharmacology of (-)deprenyl.

1. Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

2. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

3. The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle.

Review 4. The clinical physiology of side effects in long-term L-DOPA therapy.

5. Deprenyl is metabolized to methamphetamine and amphetamine in man.

6. Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor.

7. Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment.

8. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

9. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

10. Deprenyl in Parkinson's disease.

Review 1. Selegiline and Parkinson's disease. Protective and symptomatic considerations.

2. Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.

Review 3. Drug-induced sleep disturbances. Focus on nonpsychotropic medications.

4. Absence of "cheese effect" during deprenyl therapy: some recent studies.

5. Treatment of Parkinson's disease: problems with a progressing disease.

6. The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.

7. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.

Review 8. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

9. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.